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Abstract
Hierarchical random effect models are used for different purposes in
clinical research and other areas. In general, the main focus is on pop-
ulation parameters related to the expected treatment effects or group
differences among all units of an upper level (e.g. subjects in many set-
tings). Optimal design for estimation of population parameters are well
established for many models. However, optimal designs for the prediction
for the individual units may be different. Several settings are identified
in which individual prediction may be of interest. In this paper we deter-
mine optimal designs for the individual predictions, e.g. in multi-center
trials, and compare them to a conventional balanced design with respect
to treatment allocation. Our investigations show, that balanced designs
are far from optimal if the treatment effects vary strongly as compared
to the residual error and more subjects should be recruited to the active
(new) treatment in multi-center trials. Nevertheless, efficiency loss may
be limited resulting in a moderate sample size increase when individual
predictions are foreseen with a balanced allocation.
1 Introduction
Hierarchical random effect models are used for different purposes. Common
applications, e.g. in clinical research, are random effect meta analyses of sev-
eral clinical trials using individual patient data (IPD), multi-center trials as-
suming random center effects or mixed or random effect models for repeated
measurements (MMRM) for longitudinal data within subjects. Clinical trials or
meta-analyses of clinical trials may involve several populations or subgroups of
patients (e.g. defined by genetic biomarkers), where in some settings between-
population variability may be modeled using a hierarchical approach. Apart
from clinical trials or observational studies data on quality parameters of drugs
arise from hierarchical settings with multiple layers, i.e. with multiple sources
of variability according to the underlying manufacturing process, e.g. given by
manufacturing sites, production batches and samples within batches. In general,
the main focus is on population parameters related to the expected treatment
effects or group differences among all units of an upper level (e.g. trials in
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IPD meta-analyses, centers in multi-center trials, patients in longitudinal trials,
batches in quality control, etc.). Several authors considered optimal design for
estimation of population parameters (expected values of random effects) in sim-
ilar models, see, e.g. [Fedorov and Jones(2005)], [Fedorov and Leonov(2013)],
[Schwabe and Schmelter(2008)] and [Lemme et al.(2015)]. However, prediction
of the outcome in the individual units may also be of interest in several settings,
as for treatment effects in single centers to assess qualification of individual clin-
ics, manufacturing sites in manufacturing control, treatment effects in different
subpopulations of patients. In these cases, the question arises, whether optimal
designs for populations parameters can also be used for individual predictions
of random effects, whether optimal designs for individual predictions differ from
those for populations parameters and to which extent and which efficiency loss
(or sample size increase) can be anticipated if another conventional design is
chosen.
Therefore, we investigated optimal designs for random effects to be applied,
e.g. in multi-center trials and compared them to a conventional balanced design
with respect to treatment allocation.
The structure of the paper is as follows: In the second section a model of
a multi-center trial is specified and the best linear unbiased predictions of the
individual center parameters (intercepts and treatment effects) are derived. In
Section 3 analytical results are presented to characterize optimal designs for
prediction in multi-center trials. The results are illustrated by some numerical
examples. The paper is concluded by a short discussion.
2 Model Specification
We consider a multicenter trial with K different centers. In all of these centers
individuals are allocated to two treatment groups. In the first group (denoted
by x = 1) the individuals receive an active treatment while in the second group
(denoted by x = 0) a placebo or a control treatment is applied.
Denote by µi and αi the intercept (mean response at placebo or control) and
the effect of the active treatment (compared to placebo or control), respectively,
in center i = 1, ...,K, which both may vary across the centers. The response
Yij of an individual j = 1, ..., Ni in center i can be described as
Yij = µi + αixij + εij , (1)
where xij is equal to 1, if the individual belongs to the treatment group, and
xij is equal to 0 for the control (or placebo) group and εij denotes the random
variation in the response of the individuals. The individual variations εij are
assumed ot have zero mean and to be homoscedastic with common variance σ2.
The centers are assumed to be similar and, hence, representatives of a larger
entity of centers. Thus the center specific intercepts µi and treatment effects
αi can be assumed as random with (unknown) expected values E(µi) = µ and
E(αi) = α characterizing the mean intercept and mean treatment effect across
2
the centers and covariance structure Cov((µi, αi)
>) = σ2D for some 2× 2 pos-
itive definite dispersion matrix D. All random effects and all individual varia-
tions are assumed to be uncorrelated.
For the sake of simplicity we further assume that the total number N of
individuals is the same for all centers (Ni = N) and that the allocation rate is
constant across the centers, i. e. the number n of individuals in the treatment
group is the same for all centers. The design problem can then be formulated in
terms of finding the optimal allocation rate w = n/N for the treatment group.
Because of exchangeability of the individuals within each center we may sort
them in the analysis regardless of randomization in such a way that the first
n individuals j = 1, ..., n to be analyzed receive the active treatment and the
remaining N −n individuals j = n+ 1, ..., N are in the control group. Then the
experimental settings xij in (1) can be specified by
xij = xj =
{
1, j = 1, ..., n
0, j = n+ 1, ..., N
and are independent of the center i.
Hence, the multi-center model (1) can be identified as a particular case of
the random coefficient regression model
Yij = f(xj)
>βi + εij , i = 1, . . . ,K, j = 1, . . . , N (2)
investigated by [Prus and Schwabe(2016)] when the regression functions and the
center parameters are specified by f(x) = (1, x)> and βi = (µi, αi)
>, respec-
tively. In general this model can be written in vector notation as
Yi = Fβi + εi, (3)
where Yi = (Yi1, ..., YiN )
> and εi = (εi1, ..., εiN )> are the N -dimensional vec-
tors of observations and individual variations at center i, respectively, and
F = (f(x1), ..., f(xN ))
> is the within center design matrix which is equal across
all centers.
For the present multicenter model the design matrix F simplifies to
F =
(
1n 1n
1N−n 0N−n
)
,
where 1` and 0 ` denote the `-dimensional vectors with all entries equal to 1
and 0, respectively.
According to [Prus and Schwabe(2016)] (see also [Fedorov and Jones(2005)])
in model (2) the best linear unbiased predictors (BLUP)
βˆi = (F
>F + D−1)−1(F>F βˆi;ind + D
−1βˆ0) (4)
of the random parameters βi are weighted combinations of the individual esti-
mates βˆi;ind = (F
>F)−1F>Yi based only on the observations in center i and
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the the best linear unbiased estimator (BLUE) βˆ0 = (F
>F)−1F>Y¯ of the popu-
lation parameter β0 = E(βi), where Y¯ =
1
K
∑K
i=1 Yi is the mean observational
vector averaged across the centers..
We additionally assume that the center intercepts µi and the center treat-
ment effects αi are uncorrelated for all centers, i. e. D = diag(u, v), where
u = σ2µ/σ
2 > 0 and v = σ2α/σ
2 > 0 are the variance ratios of the intercepts and
the treatment effects in relation to the observational variance of the individuals.
With the standard notations Y
(T )
i · =
1
n
∑n
j=1 Yij and Y
(C)
i · =
1
N−n
∑N
j=n+1 Yij
for the mean response in the treatment (“T”) and the control (“C”) groups in
center i, Y
(T )
· · = 1K
∑K
i=1 Y
(T )
i · and Y
(C)
· · = 1K
∑K
i=1 Y
(C)
i · for the overall mean
of the treatment and the control groups, respectively, the BLUPs for the center
parameters βˆi = (µˆi, αˆi)
> of the random intercepts and the random treatment
effects βi = (µi, αi)
> in model (1) can be written as weighted averages
µˆi = c0(Y
(T )
i · − Y (T )· · ) + cY (C)i · + (1− c)Y (C)· · , (5)
where c0 =
nu
(Nu+1)(nv+1)−n2uv and c =
u(N−n)(nv+1)
(Nu+1)(nv+1)−n2uv , and
αˆi = c1Y
(T )
i · + (1− c1)Y (T )· · − c2Y (C)i · − (1− c2)Y (C)· · (6)
with weights c1 =
(Nu+1)nv−n2uv
(Nu+1)(nv+1)−n2uv and c2 =
Nu+nv+1
(Nu+1)(nv+1)−n2uv .
To measure the quality of a design we will use the mean squared error
(MSE) matrix of the BLUP βˆ =
(
βˆ
>
1 , ..., βˆ
>
K
)>
of the complete vector β =
(β>1 , ...,β
>
K)
> of all random parameters. The mean squared error (MSE) ma-
trix for the BLUP βˆ can be computed by means of the following formula :
Cov
(
βˆ − β
)
= σ2
(
1
K (1K1
>
K)⊗ (F>F)−1
+ (IK − 1K1K1>K)⊗ (F>F + D−1)−1
)
(7)
(see [Prus and Schwabe(2016)]), where I` denotes the `× ` identity matrix and
⊗ is the symbol for the Kronecker product of matrices or vectors.
Further denote by Ψα = (α1, ...,αK)
>
the vector of treatment effects for all
centers. Then Ψα = (IK ⊗ (0, 1))β and, hence,
Cov
(
Ψˆα −Ψα
)
= (IK ⊗ (0, 1)) Cov
(
βˆ − β
)
(IK ⊗ (0, 1))> (8)
for the MSE matrix of the BLUP Ψˆα = (αˆ1, ..., αˆK)
> of Ψα. Using this and
formula (7) we obtain the MSE matrix
Cov
(
Ψˆα −Ψα
)
= σ2
(
N
n(N − n)
1
K
1K1
>
K
+
v(Nu+ 1)
(Nu+ 1)(nv + 1)− n2uv (IK −
1
K
1K1
>
K)
)
. (9)
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3 Optimal Design
As individuals are interchangeable within treatment groups we may define an
exact within center design (
T C
n N − n
)
(10)
by the allocation numbers n and N − n to the treatment and control group T
and C, respectively.
For analytical purposes, we generalize this to the definition of an approxi-
mate design:
ξ =
(
T C
w 1− w
)
, (11)
where w = nN is the allocation rate to the treatment group and 1−w = N−nN is
the allocation rate to the control group. For finding an optimal design only the
optimal allocation rate w∗ to the treatment group has to be determined.
For an approximate design the definition of the MSE matrix (9) of the BLUP
Ψˆα is extended in a straightforward manner an can be rewritten (neglecting σ
2)
as :
MSE(w) =
1
Nw(1− w)
1
K
1K1
>
K
+
v(Nu+ 1)
(Nu+ 1)(Nwv + 1)−N2w2uv (IK −
1
K
1K1
>
K) (12)
in terms of the allocation rate w. The approach of approximate designs seems
in so far to be appropriate as the total number N of individuals in each center
should be sufficiently large. Otherwise optimal exact designs have to be obtained
by adequate rounding of w∗ to a multiple of 1/N (see below).
For the assessment of the MSE matrix we focus on the A-optimality criterion
which averages the mean squared errors of the center treatment effects. More
specifically, the A-criterion Φα is the trace of the MSE matrix of the prediction
Ψˆα of the center treatment effects. For an approximate design we get
Φα(w) =
1
Nw(1− w) + (K − 1)
v(Nu+ 1)
(Nu+ 1)(Nwv + 1)−N2w2uv (13)
for the criterion function Φα in terms of the allocation rate w. Because, in
general, there is no explicit solution for the optimal allocation rate, which mini-
mizes (13), we will give an insight in the qualitative behavior by some numerical
example below.
It is worth-while mentioning that the criterion (13) is convex and, therefore,
an optimal exact design may be obtained by choosing the best of two exact
designs adjacent to an optimal approximate design.
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3.1 Example.
For illustrative purposes we consider a numerical example with K = 50 centers
and N = 10 individuals in each center. Figure 1 exhibits the behavior of the
optimal allocation rate w∗ to the treatment group in dependence of the variance
ratio v of the treatment effects for some fixed values 0.01, 0.1, 0.25, 0.5 and 1, 5
of the variance ratio u of the intercept. For reasons of presentation we plot the
optimal allocation rate w∗ against the rescaled variance ratio rv = v/(1 + v) in
the spirit of intra-class correlation in order to cover all possible values of the
treatment effects variance by a finite interval ((0, 1)). Each value of the variance
ratio u of the intercepts is represented by one solid line. What can be seen from
the picture is that for fixed values of u the optimal allocation rate w∗ is equal
to 0.5 for v → 0 and increases with increasing values of the variance ratio v
of the treatment effects. The different lines associated to the different values
of u appear in descending order which means that the optimal allocation rates
decrease when the variance ratio of the intercepts gets larger.
The next figure (Figure 2) shows the behavior of the optimal allocation rate
in dependence of the variance ratio u of the intercepts for fixed values 0.01, 0.1,
0.2, 0.5 and 2 of the variance ratio v of the treatment effects, where again the
variance ratio is rescaled (ru = u/(u + 1)). Also here it can be seen that the
optimal allocation rate decreases with increasing values of u and increases with
increasing values of v.
rv
w
*
0.0 0.2 0.4 0.6 0.8 1.0
0.45
0.50
0.55
0.60
0.65
0.70
0.75
ru
w
*
0.0 0.2 0.4 0.6 0.8 1.0
0.45
0.50
0.55
0.60
0.65
0.70
0.75
Figure 1: A-optimal allocation rate w∗
to the treatment group in dependence on
the rescaled variance ratio rv = v/(1 + v)
of the treatment effects for u = 0.01, 0.1,
0.25, 0.5 and 1.5
Figure 2: A-optimal allocation rate w∗ to
the treatment group in dependence on the
rescaled variance ratio ru = u/(1 + u) of
the intercepts for v = 0.01, 0.1, 0.2, 0.5
and 2
Finally, Figures 3 and 4 present the efficiency of the equal allocation rate
w0 = 0.5 which is optimal in the fixed effects model (u = v = 0). The efficiency
6
for the A-criterion (A-efficiency) has been computed using the standard formula
eff(w0) =
Φα(w
∗)
Φα(w0)
. (14)
The efficiencies decrease with increasing values of the variance of the treatment
rv
e
ff
0.0 0.2 0.4 0.6 0.8 1.0
0.850
0.875
0.900
0.925
0.950
0.975
1.000
ru
e
ff
0.0 0.2 0.4 0.6 0.8 1.0
0.850
0.875
0.900
0.925
0.950
0.975
1.000
Figure 3: A-efficiency of the equal alloca-
tion rate w0 = 0.5 in dependence on the
rescaled variance ratio rv = v/(1 + v) of
the treatment effects for u = 0.01, 0.1,
0.25, 0.5 and 1.5
Figure 4: A-efficiency of the equal alloca-
tion rate w0 = 0.5 in dependence on the
rescaled variance ratio ru = u/(1 + u) of
the intercepts for v = 0.01, 0.1, 0.2, 0.5
and 2
effects and increase with increasing values of the variance of the intercepts.
Example cont.
For illustrative purposes we consider numerical examples with K = 50 or
K = 100 centers and N = 10 or N = 5 individuals in each center. Figures 5
and 6 exhibit the behavior of the optimal allocation rate w∗ to the treatment
group in dependence of the variance ratio q = v/u for some fixed values 0.01
(solid line), 0.1 (dashed line), 0.25 (dotted line), 0.5 (dashed-dotted line) and 1, 5
(dashed line, long dashes) of the variance ratio u of the intercept. For reasons of
presentation we plot the optimal allocation rate w∗ against the rescaled variance
ratio rq = q/(1 + q) in the spirit of intraclass correlation in order to cover all
possible values of variance ratio by a finite interval ((0, 1)). As we can observe on
the graphics, the dependence on the variance ratio is more essential for K = 100
and N = 5 than for K = 50 and N = 10.
Figures 7 and 8 presents the efficiency of the equal allocation rate w0 = 0.5
which is optimal in the fixed effects model. The efficiency is more sensible with
respect to the variance ratio in the case K = 100 and N = 5 than for K = 50
and N = 10.
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Figure 5: A-optimal allocation rate w∗
to the treatment group in dependence on
the rescaled variance ratio rq = q/(1 + q)
of the treatment effects for u = 0.01, 0.1,
0.25, 0.5, 1.5, K = 50 and N = 10
Figure 6: A-optimal allocation rate w∗
to the treatment group in dependence on
the rescaled variance ratio rq = q/(1 + q)
of the treatment effects for u = 0.01, 0.1,
0.25, 0.5, 1.5, K = 100 and N = 5
4 Discussion
As illustrated in the example, the larger the between-unit (between-trial) vari-
ability of the treatment effects the more the optimal weight deviates from equal
allocation, especially if the variance of the units’ intercepts is small. An in-
creasing heterogeneity in the treatment effect leads to a decreased precision of
the design that is optimal for population parameters: A balanced design is far
from optimal if the treatment effects vary strongly as compared to the resid-
ual error and more subjects should be recruited to the active (new) treatment
in multi-center trials. Nevertheless, it appears reassuring to the clinical trial
practitioner that the efficiency loss may be limited as in the example resulting
in a total sample size increase of about 10 - 20 % in the considered scenar-
ios if individual predictions are foreseen with a balanced allocation. Usually,
between-unit variability of treatment effects are considered to be rather small,
indicating that equal allocation may suffice. However, using the results given in
the paper, specific settings with different expectations can be assessed properly,
in order to make optimally use of a limited number of patients or sample units
to predict random effects of individual units.
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